NEW YORK (GenomeWeb News) — Thermo Fisher Scientific has completed the sale of certain assets to GE, the companies said today.

Specifically, GE acquired Thermo Fisher's HyClone cell culture media and sera, as well as its gene modulation and magnetic beads businesses, for $1.065 billion.

The businesses will become part of GE Healthcare's Life Sciences division, and will allow the company to expand its offering of tool, technologies, and services for the discovery and manufacture of new medicines, vaccines, and diagnostics, GE said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.